[go: up one dir, main page]

AR076262A1 - Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer - Google Patents

Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer

Info

Publication number
AR076262A1
AR076262A1 ARP100101142A ARP100101142A AR076262A1 AR 076262 A1 AR076262 A1 AR 076262A1 AR P100101142 A ARP100101142 A AR P100101142A AR P100101142 A ARP100101142 A AR P100101142A AR 076262 A1 AR076262 A1 AR 076262A1
Authority
AR
Argentina
Prior art keywords
heterociclical
diazepin
ona
derivatives
pharmaceutical compositions
Prior art date
Application number
ARP100101142A
Other languages
English (en)
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of AR076262A1 publication Critical patent/AR076262A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proveen en la presente compuestos usados para inhibir la enzima de desaminacion responsable de la inactivacion de compuestos terapéuticos y métodos de uso de ellos. Reivindicacion 1: El compuesto de la formula (1), en donde: uno de R1 y R2 es F y el otro está seleccionado de H y F; uno de R3 y R4 es H y el otro está seleccionado de H y OH; donde - - - - es un enlace covalente o está ausente y R4 está ausente cuando - - - - es un enlace covalente; o uno de sus ésteres de alquilo C1-6 o ésteres de alquenilo C2-6 farmacéuticamente aceptables.
ARP100101142A 2009-04-06 2010-04-06 Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer AR076262A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16711209P 2009-04-06 2009-04-06

Publications (1)

Publication Number Publication Date
AR076262A1 true AR076262A1 (es) 2011-06-01

Family

ID=42126083

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101142A AR076262A1 (es) 2009-04-06 2010-04-06 Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer

Country Status (10)

Country Link
US (1) US8324180B2 (es)
EP (1) EP2417146B1 (es)
JP (1) JP5687687B2 (es)
AR (1) AR076262A1 (es)
AU (2) AU2010234637B2 (es)
CA (1) CA2757743C (es)
ES (1) ES2593088T3 (es)
JO (1) JO3197B1 (es)
TW (1) TWI477508B (es)
WO (1) WO2010118006A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
EP2416780B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) * 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1985001871A1 (en) 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
WO1994019362A1 (en) 1993-02-23 1994-09-01 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
TW466112B (en) 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
JP2002525320A (ja) 1998-09-25 2002-08-13 ワーナー−ランバート・カンパニー アセチルジナリンとジェムシタビン、キャペシタビンまたはシスプラチンの組み合わせによる癌の化学療法
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
DE60030842T2 (de) 1999-03-01 2007-05-10 Halogenetics Inc., Aventura VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
JP3942414B2 (ja) 2000-11-29 2007-07-11 三井化学株式会社 Ｌ型核酸誘導体およびその合成法
AU2002236765A1 (en) 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
JP2006507255A (ja) 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド ウイルス疾患の治療のための１，３，５−トリアジン
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TW200606159A (en) 2004-07-30 2006-02-16 Pharmaessentia Corp Stereoselective synthesis of β-nucleosides
CA2586687A1 (en) 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
US20080080200A1 (en) 2006-09-29 2008-04-03 Grote Industries, Inc Lighting systems using light active sheet material with integrated leadframe, and methods for manufacturing the same
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
EP2416780B1 (en) 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
ES2628609T3 (es) 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer

Also Published As

Publication number Publication date
TW201102397A (en) 2011-01-16
CA2757743A1 (en) 2010-10-14
AU2016213881B2 (en) 2018-03-22
JP5687687B2 (ja) 2015-03-18
CA2757743C (en) 2017-10-10
AU2016213881A1 (en) 2016-09-01
EP2417146A1 (en) 2012-02-15
EP2417146B1 (en) 2016-07-13
JP2012522840A (ja) 2012-09-27
JO3197B1 (ar) 2018-03-08
WO2010118006A1 (en) 2010-10-14
TWI477508B (zh) 2015-03-21
AU2010234637B2 (en) 2016-05-12
AU2010234637A1 (en) 2011-11-10
US8324180B2 (en) 2012-12-04
ES2593088T3 (es) 2016-12-05
US20100279966A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20130149A1 (es) Derivados de la cromenona con actividad anti-tumoral
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BRPI1015568B8 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
PE20090362A1 (es) Derivados de piperidina/piperazina como moduladores de dgat
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.
ECSP066693A (es) Derivados de bencimidazol
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc

Legal Events

Date Code Title Description
FG Grant, registration